Ikena Oncology inks $43M cash grab in all-stock deal for Pionyr

Ikena Oncology said it added about $43 million to its runway after making an all-stock acquisition of the private startup Pionyr Immunotherapeutics, a clinical-stage company that Gilead decided not to fully buy out earlier this year.

Ikena had slimmed down its pipeline in November as…
Click here to view original post

Advertisement — Advertise with Biotech Networks